Neoadjuvant Endocrine Therapy vs De-Escalated Chemotherapy for HR-Positive, HER2-Positive Early Breast Cancer
Oleg Gluz, MD, Breast Cancer Niederrhein, Germany, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab followed by standard endocrine therapy and trastuzumab plus pertuzumab for 1 year (with or without adjuvant chemotherapy) in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Results from this trial showed encouraging survival outcomes for patients treated with neoadjuvant endocrine therapy or paclitaxel plus trastuzumab and pertuzumab followed by pCR-guided chemotherapy and adjuvant trastuzumab plus pertuzumab and endocrine therapy.
Dr Gluz presented these results at the 2024 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.
Source:
Gluz O, Nitz UA, Christgen M, et al. Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial. Presented at the 2024 ESMO Congress. September 13-17, 2024. Abstract LBA17
